Cetera Advisor Networks LLC Exelixis, Inc. Transaction History

Cetera Advisor Networks LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$20.17 - $23.93 $54,902 - $65,137	2,722 Added 19.51%	16,672 $395,000
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $268,537 - $336,613	13,950 New	13,950 $334,000
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $160,820 - $186,942	10,750 New	10,750 $172,000
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $46,796 - $60,992	-2,264 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $37,265 - $62,078	2,264 New	2,264 $54,000
Q4 2018 Feb 15, 2019	SELL	$13.65 - $21.8 $145,727 - $232,736	-10,676 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $169,428 - $239,142	10,676 New	10,676 $189,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.